• 

  May 14, 2026

  Why Hypoparathyroidism May Be the Best First Market for Biofabricated Endocrine Tissue Therapeutics

  R.D. Solorzano

• 

  May 1, 2026

  XellSmart Launches Phase II Trial of Off-the-Shelf iPSC Cell Therapy for Parkinson’s

  R.D. Solorzano

• 

  April 30, 2026

  Eli Lilly Pays Up to $7B for Kelonia’s In Vivo CAR-T Platform and What It Means for Cell Therapy Manufacturing

  R.D. Solorzano

• 

  April 27, 2026

  The Organ-on-Chip, Microphysiological Systems Landscape, NAMs: A Business Overview

  R.D. Solorzano

• 

  April 24, 2026

  Linton Lifesciences Launches Biofabricated NAMs: Rebuilding the Missing Layer Between Biology and Decision-Making

  R.D. Solorzano

• 

  March 3, 2026

  Cellares Raises $257M to Industrialize Cell Therapy Manufacturing

  R.D. Solorzano

• 

  December 15, 2025

  Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development

  R.D. Solorzano

• 

  December 11, 2025

  Inside Curi Bio’s Human Tissue Platforms: How They Work, What the $10M Series B Will Accelerate, and Why It Matters

  R.D. Solorzano

• 

  November 20, 2025

  InSphero Acquires Doppl SA, Expanding Its 3D Cell Culture Portfolio with the Gri3D® Platform

  R.D. Solorzano

• 

  October 13, 2025

  L’Oréal and AMKbiotech Partner to Unlock Next-Generation Insights in Skin Biology with High-Plex Imaging

  R.D. Solorzano